ISPOR - HPR125 Novel Drug Approvals By the U.S. Food and Drug Administration in Rare Diseases: Findings from 2020–2023

HPR125 Novel Drug Approvals By the U.S. Food and Drug Administration in Rare Diseases: Findings from 2020–2023

Abstract

Authors

A Dubey P Gupta N Ranjan P Ray J Kumar J Shaikh

Full Text Cite This Article

Back to Volume 27, Supplemental Issue 6S

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now